Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

MYC dysregulation in the progression of multiple myeloma.

Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, Van Wier SA, Riggs DL, Ahmann G, Chesi M, Viswanatha DS, Kumar SK, Dispenzieri A, Gonzalez-Calle V, Kyle RA, O'Dwyer M, Rajkumar SV, Kortüm KM, Keats JJ; MMRF CoMMpass Network, Fonseca R, Stewart AK, Kuehl WM, Braggio E, Bergsagel PL.

Leukemia. 2019 Aug 22. doi: 10.1038/s41375-019-0543-4. [Epub ahead of print] No abstract available.

PMID:
31439946
2.

Detailing the genomic landscape of myeloma.

Bergsagel PL, Kuehl WM.

Blood. 2018 Aug 9;132(6):554-555. doi: 10.1182/blood-2018-06-857508. No abstract available.

3.

Novel near-diploid ovarian cancer cell line derived from a highly aneuploid metastatic ovarian tumor.

Rozenblum E, Sotelo-Silveira JR, Kim GY, Zhu JY, Lau CC, McNeil N, Korolevich S, Liao H, Cherry JM, Munroe DJ, Ried T, Meltzer PS, Kuehl WM, Roschke AV.

PLoS One. 2017 Aug 7;12(8):e0182610. doi: 10.1371/journal.pone.0182610. eCollection 2017.

4.

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.

Mitra AK, Harding T, Mukherjee UK, Jang JS, Li Y, HongZheng R, Jen J, Sonneveld P, Kumar S, Kuehl WM, Rajkumar V, Van Ness B.

Blood Cancer J. 2017 Jun 30;7(6):e581. doi: 10.1038/bcj.2017.56.

5.

Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.

Simmons JK, Michalowski AM, Gamache BJ, DuBois W, Patel J, Zhang K, Gary J, Zhang S, Gaikwad S, Connors D, Watson N, Leon E, Chen JQ, Kuehl WM, Lee MP, Zingone A, Landgren O, Ordentlich P, Huang J, Mock BA.

Mol Cancer Ther. 2017 Sep;16(9):2008-2021. doi: 10.1158/1535-7163.MCT-17-0171. Epub 2017 May 18.

6.

Frequent occurrence of large duplications at reciprocal genomic rearrangement breakpoints in multiple myeloma and other tumors.

Demchenko Y, Roschke A, Chen WD, Asmann Y, Bergsagel PL, Kuehl WM.

Nucleic Acids Res. 2016 Sep 30;44(17):8189-98. doi: 10.1093/nar/gkw527. Epub 2016 Jun 27.

7.

VOLIN and KJON-Two novel hyperdiploid myeloma cell lines.

Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T.

Genes Chromosomes Cancer. 2016 Nov;55(11):890-901. doi: 10.1002/gcc.22388. Epub 2016 Jul 12.

PMID:
27311012
8.

Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.

Vallabhapurapu SD, Noothi SK, Pullum DA, Lawrie CH, Pallapati R, Potluri V, Kuntzen C, Khan S, Plas DR, Orlowski RZ, Chesi M, Kuehl WM, Bergsagel PL, Karin M, Vallabhapurapu S.

Nat Commun. 2015 Oct 12;6:8428. doi: 10.1038/ncomms9428.

PMID:
26455434
9.

Repair of DNA double-strand breaks by templated nucleotide sequence insertions derived from distant regions of the genome.

Onozawa M, Zhang Z, Kim YJ, Goldberg L, Varga T, Bergsagel PL, Kuehl WM, Aplan PD.

Proc Natl Acad Sci U S A. 2014 May 27;111(21):7729-34. doi: 10.1073/pnas.1321889111. Epub 2014 May 12.

10.

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri A, Ponzoni M, Marcatti M, Richardson PG, Carrasco R, Kimmelman AC, Wong KK, Caligaris-Cappio F, Blandino G, Kuehl WM, Anderson KC, Tonon G.

Nat Med. 2014 Jun;20(6):599-606. doi: 10.1038/nm.3562. Epub 2014 May 11.

11.

Complex IGH rearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets.

Kim GY, Gabrea A, Demchenko YN, Bergsagel L, Roschke AV, Kuehl WM.

Genes Chromosomes Cancer. 2014 Jun;53(6):467-74. doi: 10.1002/gcc.22158. Epub 2014 Mar 3.

12.

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.

Affer M, Chesi M, Chen WG, Keats JJ, Demchenko YN, Roschke AV, Van Wier S, Fonseca R, Bergsagel PL, Kuehl WM.

Leukemia. 2014 Aug;28(8):1725-1735. doi: 10.1038/leu.2014.70. Epub 2014 Feb 12.

13.

TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.

Simmons JK, Patel J, Michalowski A, Zhang S, Wei BR, Sullivan P, Gamache B, Felsenstein K, Kuehl WM, Simpson RM, Zingone A, Landgren O, Mock BA.

Mol Oncol. 2014 Mar;8(2):261-72. doi: 10.1016/j.molonc.2013.11.007. Epub 2013 Dec 3.

14.

Degree of focal immunoglobulin heavy chain locus deletion as a measure of B-cell tumor purity.

Bergsagel PL, Kuehl WM.

Leukemia. 2013 Oct;27(10):2067-8. doi: 10.1038/leu.2013.139. Epub 2013 May 6. No abstract available.

15.

Molecular pathogenesis of multiple myeloma and its premalignant precursor.

Kuehl WM, Bergsagel PL.

J Clin Invest. 2012 Oct;122(10):3456-63. doi: 10.1172/JCI61188. Epub 2012 Oct 1. Review.

16.

MYC addiction: a potential therapeutic target in MM.

Kuehl WM, Bergsagel PL.

Blood. 2012 Sep 20;120(12):2351-2.

PMID:
22996653
17.

Mouse models can predict cancer therapy.

Kuehl WM.

Blood. 2012 Jul 12;120(2):238-40. doi: 10.1182/blood-2012-04-422501.

PMID:
22791771
18.

Comprehensive identification of somatic mutations in chronic lymphocytic leukemia.

Bergsagel PL, Kuehl WM.

Cancer Cell. 2011 Jul 12;20(1):5-7. doi: 10.1016/j.ccr.2011.06.023.

19.

Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.

Zingone A, Kuehl WM.

Semin Hematol. 2011 Jan;48(1):4-12. doi: 10.1053/j.seminhematol.2010.11.003. Review.

20.

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.

Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, Hurt EM, Shaffer AL, Kuehl WM, Staudt LM.

Blood. 2011 Feb 24;117(8):2396-404. doi: 10.1182/blood-2010-04-278788. Epub 2010 Dec 16.

21.

Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.

Mailankody S, Mena E, Yuan CM, Balakumaran A, Kuehl WM, Landgren O.

Leuk Lymphoma. 2010 Dec;51(12):2159-70. doi: 10.3109/10428194.2010.525725. Epub 2010 Oct 20. Review.

PMID:
20958231
22.

A critical role for the NFkB pathway in multiple myeloma.

Demchenko YN, Kuehl WM.

Oncotarget. 2010 May;1(1):59-68.

23.

Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Weiss BM, Kuehl WM.

Expert Rev Hematol. 2010 Apr;3(2):165-74. doi: 10.1586/ehm.10.13. Review.

24.

Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms.

Zingone A, Cultraro CM, Shin DM, Bean CM, Morse HC 3rd, Janz S, Kuehl WM.

Leukemia. 2010 Jun;24(6):1171-8. doi: 10.1038/leu.2010.50. Epub 2010 Apr 15.

25.

Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.

Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM.

Blood. 2010 Apr 29;115(17):3541-52. doi: 10.1182/blood-2009-09-243535. Epub 2010 Jan 6.

26.

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H; International Myeloma Working Group.

Leukemia. 2009 Dec;23(12):2210-21. doi: 10.1038/leu.2009.174. Epub 2009 Oct 1. Review.

27.

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.

Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM.

Cell. 2009 May 29;137(5):873-86. doi: 10.1016/j.cell.2009.03.046. Epub 2009 May 14.

28.

OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus.

Våtsveen TK, Tian E, Kresse SH, Meza-Zepeda LA, Gabrea A, Glebov O, Dai HY, Sundan A, Kuehl WM, Børset M.

Leuk Res. 2009 Dec;33(12):1670-7. doi: 10.1016/j.leukres.2009.03.001. Epub 2009 Apr 23.

PMID:
19395026
29.

A monoclonal gammopathy precedes multiple myeloma in most patients.

Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM.

Blood. 2009 May 28;113(22):5418-22. doi: 10.1182/blood-2008-12-195008. Epub 2009 Feb 20.

30.

A der(8)t(8;11) chromosome in the Karpas-620 myeloma cell line expresses only cyclin D1: yet both cyclin D1 and MYC are repositioned in close proximity to the 3'IGH enhancer.

Dib A, Glebov OK, Shou Y, Singer RH, Kuehl WM.

DNA Repair (Amst). 2009 Mar 1;8(3):330-5. doi: 10.1016/j.dnarep.2008.11.010. Epub 2008 Dec 27.

31.

WSU-WM and BCWM.1 should not be assumed to represent Waldenström macroglobulinemia cell lines.

Bergsagel PL, Kuehl WM.

Blood. 2008 Aug 1;112(3):917. doi: 10.1182/blood-2008-05-154831. No abstract available.

PMID:
18650470
32.

Characterization of MYC translocations in multiple myeloma cell lines.

Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM.

J Natl Cancer Inst Monogr. 2008;(39):25-31. doi: 10.1093/jncimonographs/lgn011.

33.

Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.

Gabrea A, Martelli ML, Qi Y, Roschke A, Barlogie B, Shaughnessy JD Jr, Sawyer JR, Kuehl WM.

Genes Chromosomes Cancer. 2008 Jul;47(7):573-90. doi: 10.1002/gcc.20563.

34.

Modeling multiple myeloma by AID-dependent conditional activation of MYC.

Kuehl WM.

Cancer Cell. 2008 Feb;13(2):85-7. doi: 10.1016/j.ccr.2008.01.022.

35.

Genetic events in the pathogenesis of multiple myeloma.

Chng WJ, Glebov O, Bergsagel PL, Kuehl WM.

Best Pract Res Clin Haematol. 2007 Dec;20(4):571-96. Review.

36.

Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.

Chng WJ, Kuehl WM, Bergsagel PL, Fonseca R.

Leukemia. 2008 Feb;22(2):459-61. Epub 2007 Sep 6. No abstract available. Erratum in: Leukemia. 2008 Feb;22(2):462.

PMID:
17805328
37.

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD Jr, Kuehl WM, Staudt LM.

Cancer Cell. 2007 Aug;12(2):115-30.

38.

Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma.

Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, Dave SS, Tan B, Zhao H, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Campo E, Jaffe ES, Smeland EB, Fisher RI, Kuehl WM, Chan WC, Staudt LM.

J Exp Med. 2007 Mar 19;204(3):633-43. Epub 2007 Mar 12.

39.

CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.

Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, Barlogie B, Shaughnessy JD Jr.

Blood. 2007 Jun 1;109(11):4995-5001. Epub 2007 Feb 15.

40.

Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma.

Dib A, Barlogie B, Shaughnessy JD Jr, Kuehl WM.

Blood. 2007 Feb 1;109(3):1337-8. No abstract available.

PMID:
17244692
41.

Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression.

Dib A, Peterson TR, Raducha-Grace L, Zingone A, Zhan F, Hanamura I, Barlogie B, Shaughnessy J Jr, Kuehl WM.

Cell Div. 2006 Oct 18;1:23. doi: 10.1186/1747-1028-1-23.

42.

Early genetic events provide the basis for a clinical classification of multiple myeloma.

Kuehl WM, Bergsagel PL.

Hematology Am Soc Hematol Educ Program. 2005:346-52.

PMID:
16304402
43.

Molecular pathogenesis and a consequent classification of multiple myeloma.

Bergsagel PL, Kuehl WM.

J Clin Oncol. 2005 Sep 10;23(26):6333-8. Review.

PMID:
16155016
44.

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr.

Blood. 2005 Jul 1;106(1):296-303. Epub 2005 Mar 8.

45.

Advances in biology of multiple myeloma: clinical applications.

Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC.

Blood. 2004 Aug 1;104(3):607-18. Epub 2004 Apr 15. Review.

PMID:
15090448
46.

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.

Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM.

Cancer Cell. 2004 Feb;5(2):191-9.

47.

Genetics and cytogenetics of multiple myeloma: a workshop report.

Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H.

Cancer Res. 2004 Feb 15;64(4):1546-58.

48.

Advances in biology and therapy of multiple myeloma.

Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G.

Hematology Am Soc Hematol Educ Program. 2003:248-78. Review.

PMID:
14633785
49.

Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma.

Bergsagel PL, Kuehl WM.

Immunol Rev. 2003 Aug;194:96-104. Review.

PMID:
12846810
50.

Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions.

Schop RF, Kuehl WM, Van Wier SA, Ahmann GJ, Price-Troska T, Bailey RJ, Jalal SM, Qi Y, Kyle RA, Greipp PR, Fonseca R.

Blood. 2002 Oct 15;100(8):2996-3001.

PMID:
12351413

Supplemental Content

Loading ...
Support Center